Latest News

Ovarian Cancer - Anticancer Agents

QUADRA Demonstrates Late-Line Ovarian Cancer Benefit With Niraparib

  • 08 Apr 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Heavily pretreated ovarian cancer patients may experience a survival benefit from niraparib...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof QUADRA Demonstrates Late-Line Ovarian Cancer Benefit With Niraparib

Thoracic Malignancies - Mesothelioma - Clinical Research - Immunotherapy

CAR T-Cell Therapy Shows Potential Against Malignant Pleural Disease

  • 03 Apr 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Early results suggest CAR T-cell therapy may be feasible for patients with mesothelin-expressing thoracic tumours...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof CAR T-Cell Therapy Shows Potential Against Malignant Pleural Disease

Non-Small Cell Lung Cancer - Anticancer Agents - Immunotherapy

IMpower150 ITT Analysis Shows Improved OS With Atezolizumab Plus Chemotherapy

  • 29 Mar 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Some patients with metastatic non-squamous non-small-cell lung cancer may derive a survival benefit from the addition of atezolizumab to first-line bevacizumab with carboplatin plus paclitaxel

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof IMpower150 ITT Analysis Shows Improved OS With Atezolizumab Plus Chemotherapy

Breast Cancer - Anticancer Agents

Concurrent Letrozole May Boost ER-Positive, HER2-Negative Neoadjuvant Chemotherapy Response

  • 26 Mar 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Adding oestrogen deprivation therapy to neoadjuvant chemotherapy may improve response rates for Chinese women with locally advanced ER-positive, HER2-negative breast cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Concurrent Letrozole May Boost ER-Positive, HER2-Negative Neoadjuvant Chemotherapy Response

Colon and Rectal Cancer - Personalised/Precision Medicine - Anticancer Agents

Pertuzumab Plus Trastuzumab Shows Promise For HER2-Amplified Metastatic CRC

  • 14 Mar 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

The MyPathway basket trial adds support for dual HER2-targeted therapy for HER2-amplified metastatic colorectal cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Pertuzumab Plus Trastuzumab Shows Promise For HER2-Amplified Metastatic CRC

Prostate Cancer - Immunotherapy

PROSTVAC Ineffective For Metastatic CRPC (Open access)

  • 06 Mar 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Negative findings for the phase III trial of viral vector-based immunotherapy in castration-resistant prostate cancer patients with no or minimal symptoms...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof PROSTVAC Ineffective For Metastatic CRPC (Open access)

Breast Cancer - Anticancer Agents - Supportive Measures

Denosumab Use Boosts Disease-Free Survival For HR-Positive Early Breast Cancer Patients

  • 21 Feb 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Combining adjuvant aromatase inhibitor therapy with denosumab extends disease-free survival for women with early-stage hormone-receptor positive breast cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Denosumab Use Boosts Disease-Free Survival For HR-Positive Early Breast Cancer Patients

Breast Cancer - Clinical Research - Anticancer Agents - Immunotherapy

Pembrolizumab–Trastuzumab May Offer PANACEA For Trastuzumab-Resistant Breast Cancer

  • 13 Feb 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

For patients with advanced HER2-positive breast cancer who have progressed on trastuzumab, combining the HER2 inhibitor with pembrolizumab may be an effective option...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Pembrolizumab–Trastuzumab May Offer PANACEA For Trastuzumab-Resistant Breast Cancer

Breast Cancer - Anticancer Agents

Disease-Free Survival ‘Appropriate’ Surrogate Endpoint For HER2-Positive Early Breast Cancer

  • 31 Jan 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Overall survival can be successfully predicted from disease-free survival for women with HER2-positive early breast...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Disease-Free Survival ‘Appropriate’ Surrogate Endpoint For HER2-Positive Early Breast Cancer

Immunotherapy - Complications/Toxicities of Treatment

PD-1 Inhibitor Efficacy Predicted By Immune-Related Adverse Events

  • 30 Jan 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients who experience immune-related adverse events during nivolumab or pembrolizumab monotherapy may have a higher chance of achieving an objective response than those who do not...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof PD-1 Inhibitor Efficacy Predicted By Immune-Related Adverse Events

Haematological Malignancies - Clinical Research - Anticancer Agents - Immunotherapy

Ibrutinib Plus Nivolumab May Be ‘Promising’ For CLL Richter’s Transformation

  • 21 Jan 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Combining ibrutinib with nivolumab achieved clinical response in chronic lymphocytic leukaemia patients with Richter’s transformation...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Ibrutinib Plus Nivolumab May Be ‘Promising’ For CLL Richter’s Transformation

Cancer in Special Situations

Undiagnosed HBV, HCV Infection Rate At Cancer Diagnosis Warrants Screening

  • 18 Jan 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Screening for hepatitis B and C viral infection at time of cancer diagnosis may be helpful...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Undiagnosed HBV, HCV Infection Rate At Cancer Diagnosis Warrants Screening

Oesophageal Cancer - Surgical Oncology

Hybrid Minimally Invasive Oesophagectomy May Reduce Resection Complications

  • 11 Jan 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Morbidity and mortality among oesophageal cancer patients undergoing resection may be prevented by switching to a hybrid minimally invasive procedure...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Hybrid Minimally Invasive Oesophagectomy May Reduce Resection Complications

Non-Small Cell Lung Cancer - Immunotherapy - Complications/Toxicities of Treatment

Autoimmune Markers Linked To Immunotherapy Efficacy, Adverse Events

  • 03 Jan 2019
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Researchers say that testing for autoimmune antibodies before initiating checkpoint inhibitor therapy could aid in determining the risk–benefit ratio for patients with advanced non-small-cell lung cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Autoimmune Markers Linked To Immunotherapy Efficacy, Adverse Events

Renal Cell Cancer - Anticancer Agents - Surgical Oncology

SURTIME Indicates Role For Sunitinib Before Cytoreductive Nephrectomy In mRCC Patients

  • 18 Dec 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Immediate surgery may not be the best option for patients with metastatic renal cell carcinoma...

view detailsof SURTIME Indicates Role For Sunitinib Before Cytoreductive Nephrectomy In mRCC Patients